Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 14, 2006; 12(46): 7451-7459
Published online Dec 14, 2006. doi: 10.3748/wjg.v12.i46.7451
Published online Dec 14, 2006. doi: 10.3748/wjg.v12.i46.7451
Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases
David A Scott, Oral Health and Systemic Disease Research Group, and Department of Pharmacology and Toxicology, University of Louisville, Kentucky, United States
Michael Martin, Oral Health and Systemic Disease Research Group, and Department of Microbiology and Immunology, University of Louisville, Kentucky, United States
Author contributions: All authors contributed equally to the work.
Correspondence to: David A Scott, Oral Health and Systemic Disease Research Group, University of Louisville School of Dentistry, 501 South Preston Street, Louisville, KY, 40292, United States. dascot07@louisville.edu
Telephone: +1-502-8528905 Fax: +1-502-8524052
Received: August 3, 2006
Revised: October 12, 2006
Accepted: October 18, 2006
Published online: December 14, 2006
Revised: October 12, 2006
Accepted: October 18, 2006
Published online: December 14, 2006
Core Tip